Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Clin Cancer Res
    February 2026
  1. ZHU X, Alvarez EA, Umetsu SE, Chapman JS, et al
    Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies.
    Clin Cancer Res. 2026 Feb 13. doi: 10.1158/1078-0432.CCR-25-4043.
    >> Share

    January 2026
  2. CHO HW, Park JY, Lim MC, Kim BG, et al
    Maintenance of PARP Inhibitor Rechallenge Plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.
    Clin Cancer Res. 2026 Jan 29. doi: 10.1158/1078-0432.CCR-25-2916.
    >> Share

  3. BEINSE G, Taly V, Leary A, Baures A, et al
    Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial.
    Clin Cancer Res. 2026 Jan 15. doi: 10.1158/1078-0432.CCR-25-2959.
    >> Share

  4. BRODSKY AL, Asare A, Fellman B, Anderson K, et al
    Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights.
    Clin Cancer Res. 2026 Jan 13. doi: 10.1158/1078-0432.CCR-25-1616.
    >> Share

  5. BLANC-DURAND F, Genestie C, Nikolaev S, Leman R, et al
    ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial.
    Clin Cancer Res. 2026 Jan 8. doi: 10.1158/1078-0432.CCR-25-2758.
    >> Share

    December 2025
  6. ZOELLER JJ, Tammali R, Dodd RB, Patel NV, et al
    Derivation of AZD5335, a Novel FRalpha-Targeted TOP1i-Loaded ADC, for the Treatment of FRalpha-Expressing Cancers.
    Clin Cancer Res. 2025;31:5261-5275.
    >> Share

  7. HOLLIS RL, Miller A, Lankes HA, Wong KK, et al
    Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
    Clin Cancer Res. 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-3042.
    >> Share

  8. PODDER V, Coleman RL, Hagemann AR, Singhania P, et al
    Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.
    Clin Cancer Res. 2025 Dec 2. doi: 10.1158/1078-0432.CCR-25-2819.
    >> Share

    October 2025
  9. VENEGAS L, Hodgson A, Oza AM
    Biomarkers in High-Grade Serous Ovarian Cancer: Context is everything.
    Clin Cancer Res. 2025 Oct 30. doi: 10.1158/1078-0432.CCR-25-2851.
    >> Share

  10. CARBALLO EV, Gonzalez-Ericsson P, Lehmann BD, Taylor BC, et al
    The impact of JAK1 pathogenic variants and MHC-I expression on response to immune checkpoint inhibition in endometrial cancer.
    Clin Cancer Res. 2025 Oct 10. doi: 10.1158/1078-0432.CCR-25-1442.
    >> Share

  11. ERICKSON BK, Bailey H, Arend RC, El-Rayes D, et al
    Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer.
    Clin Cancer Res. 2025 Oct 6. doi: 10.1158/1078-0432.CCR-25-1878.
    >> Share

    August 2025
  12. DA CRUZ PAULA A, Zhu Y, Brown DN, Issa Bhaloo S, et al
    Evolution and co-occurrence of PI3K pathway gene mutations in endometrial carcinoma molecular subtypes at the single-cell level.
    Clin Cancer Res. 2025 Aug 20. doi: 10.1158/1078-0432.CCR-25-1237.
    >> Share

  13. RICHARDSON DL, Quintanilha JCF, Danziger N, Li G, et al
    Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
    Clin Cancer Res. 2025;31:3599.
    >> Share

  14. KNISELY A, Dai Y, Barlow GL, Lee S, et al
    Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities.
    Clin Cancer Res. 2025 Aug 1. doi: 10.1158/1078-0432.CCR-25-0512.
    >> Share

    July 2025
  15. NGOI NYL, Choi CH, Zhu J, Lim D, et al
    Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trial.
    Clin Cancer Res. 2025 Jul 24. doi: 10.1158/1078-0432.CCR-25-0201.
    >> Share

  16. RAI L, Ravaggi A, Bignotti E, Hollis RL, et al
    Oxford Classic-defined EMT risk stratification of High Grade Serous Ovarian cancer for guiding treatment decisions.
    Clin Cancer Res. 2025 Jul 24. doi: 10.1158/1078-0432.CCR-24-4250.
    >> Share

  17. MARCHENKO S, Goernitz N, Zoern WA, Joosten M, et al
    Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-Grade Serous Tubo-ovarian Cancer.
    Clin Cancer Res. 2025 Jul 15. doi: 10.1158/1078-0432.CCR-24-2794.
    >> Share

    June 2025
  18. DE GROOT AF, Cohen D, Heijns JB, Mandigers CMPW, et al
    Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01).
    Clin Cancer Res. 2025 Jun 10. doi: 10.1158/1078-0432.CCR-24-3402.
    >> Share

  19. LAGOS G, Groisberg R, Elliott A, Dizon DS, et al
    Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma.
    Clin Cancer Res. 2025;31:2210-2221.
    >> Share

    May 2025
  20. CONCIN N, Braicu I, Combe P, Berger R, et al
    GANNET53 Part II: A European Phase I/II Trial of the HSP90 inhibitor Ganetespib in high-grade Platinum-Resistant Ovarian Cancer - A Study of the GANNET53 consortium.
    Clin Cancer Res. 2025 May 28. doi: 10.1158/1078-0432.CCR-24-3705.
    >> Share

  21. COLLET L, Ardin M, Venet D, Berthet J, et al
    Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-2712.
    >> Share

  22. KIM N, Kim YN, Lee K, Park E, et al
    Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and Plasma.
    Clin Cancer Res. 2025 May 13. doi: 10.1158/1078-0432.CCR-24-4263.
    >> Share

  23. CHUI MH, Kang EY, Kahn RM, Chiang S, et al
    Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of Ovarian Low-Grade Serous Tumors with Histologic Transformation.
    Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-3168.
    >> Share

    April 2025
  24. KAAKS R, Cooley V, Mukama T, Teras LR, et al
    A Prospective Study Consortium for the Discovery and Validation of Early Detection Markers for Ovarian Cancer ("PREDICT") - Baseline findings for CA125.
    Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1845.
    >> Share

  25. LEE JM, Miller A, Rose PG, AlHilli M, et al
    Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial.
    Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3877.
    >> Share

    March 2025
  26. COSCIA F, Nielsen AB, Weigert M, Watters K, et al
    A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer.
    Clin Cancer Res. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-1763.
    >> Share

  27. GARG V, Oza AM
    Precision Endocrine Therapy in Endometrial Cancer: Has its time finally come?
    Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3905.
    >> Share

  28. BANERJEE S, Ghisoni E, Wolfer A, Ottevanger PB, et al
    Bevacizumab, atezolizumab and acetylsalicylic acid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study.
    Clin Cancer Res. 2025 Mar 18. doi: 10.1158/1078-0432.CCR-24-3368.
    >> Share

  29. EERKENS AL, Esajas MD, Brummel K, Vledder A, et al
    Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial.
    Clin Cancer Res. 2025;31:1016-1026.
    >> Share

  30. PARK J, Joung JG, Lim MC, Lee J, et al
    Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial.
    Clin Cancer Res. 2025 Mar 5. doi: 10.1158/1078-0432.CCR-24-3753.
    >> Share

    February 2025
  31. MICHAELI O, Kim SY, Mitchell SG, Jongmans MCJ, et al
    Update on Cancer Screening in Children with Syndromes of Bone Lesions, Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome, and Other Rare Syndromes.
    Clin Cancer Res. 2025;31:457-465.
    >> Share

    January 2025
  32. ALQAISI HA, Cohn DE, Chern JY, Duska LR, et al
    Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant/refractory high grade ovarian cancer (NCI trial).
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3128.
    >> Share

  33. CHAE YK, Corthell L, Patel SP, Edwards R, et al
    A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers.
    Clin Cancer Res. 2025;31:308-315.
    >> Share

    December 2024
  34. SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
    Clin Cancer Res. 2024;30:5681-5692.
    >> Share

  35. SEO A, Xiao W, Gjyshi O, Yoshida-Court K, et al
    Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation.
    Clin Cancer Res. 2024 Dec 16. doi: 10.1158/1078-0432.CCR-24-2343.
    >> Share

    November 2024
  36. GREEN AK, Zhou Q, Iasonos A, Zammarrelli WA, et al
    A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
    Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999.
    >> Share

    October 2024
  37. BRAVO MELGAR J, Laoui D
    Chemotherapy Sparks Tertiary Lymphoid Structures in Metastatic Ovarian Cancer.
    Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-24-2738.
    >> Share

  38. CHAE YK, Othus M, Patel SP, Wilkinson KJ, et al
    SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-0606.
    >> Share

  39. SOBERANIS PINA P, Clemens K, Bubie A, Grant B, et al
    Genomic landscape of circulating tumor DNA and real-world outcomes in advanced endometrial cancer.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-2105.
    >> Share

    September 2024
  40. JEON SH, You G, Park J, Chung Y, et al
    Anti-4-1BBxPDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
    Clin Cancer Res. 2024;30:4155-4166.
    >> Share

  41. JOHANNET P, Friedman CF
    The intrauterine device: how to deploy this strategy in the molecular world?
    Clin Cancer Res. 2024 Sep 10. doi: 10.1158/1078-0432.CCR-24-2034.
    >> Share

    August 2024
  42. LANICKOVA T, Hensler M, Kasikova L, Vosahlikova S, et al
    Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.
    Clin Cancer Res. 2024 Aug 20. doi: 10.1158/1078-0432.CCR-24-1594.
    >> Share

  43. MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al
    Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.
    Clin Cancer Res. 2024;30:3640.
    >> Share

  44. BLANC-DURAND F, Ngoi NYL, Lim DG, Tan DSP, et al
    Unveiling Commonalities: Exploring Shared Characteristics in Clear Cell Carcinomas of the Gynecologic Tract.
    Clin Cancer Res. 2024 Aug 14. doi: 10.1158/1078-0432.CCR-24-1205.
    >> Share

    July 2024
  45. RICHARDSON DL, Quintanilha JCF, Danziger N, Li G, et al
    Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice.
    Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-1225.
    >> Share

  46. BONFILL-TEIXIDOR E, Neva-Alejo A, Arias A, Cuartas I, et al
    Cervical Cancer Evades the Host Immune System Through the Inhibition of Type I Interferon and CXCL9 by LIF.
    Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-0385.
    >> Share

  47. CORTES JE, Abruzzese E, Cardonick EH, Hernandez-Diaz S, et al
    Perspectives on drug development for the treatment of chronic myeloid leukemia in pregnant patients and patients who are breastfeeding.
    Clin Cancer Res. 2024 Jul 5. doi: 10.1158/1078-0432.CCR-24-0826.
    >> Share

    June 2024
  48. BOWEN MB, Melendez B, Zhang Q, Yang RK, et al
    Long-term follow-up of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer reveals relapse characterized by immune exhaustion.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0362.
    >> Share

  49. LEE HHY, Chow KL, Wong HS, Chong TY, et al
    Inhibition of aberrantly overexpressed Polo-like kinase 4 is a potential effective treatment for DNA damage repair-deficient uterine leiomyosarcoma.
    Clin Cancer Res. 2024 Jun 7. doi: 10.1158/1078-0432.CCR-23-3720.
    >> Share

  50. SANER FAM, Takahashi K, Budden T, Pandey A, et al
    Concurrent RB1 Loss and BRCA-Deficiency Predicts Enhanced Immunological Response and Long-Term Survival in Tubo-Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-3552.
    >> Share

    May 2024
  51. CORBAUX P, Freyer G, Glehen O, You B, et al
    Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
    Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-24-0507.
    >> Share

  52. HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al
    Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial.
    Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341.
    >> Share

  53. SHETH SS, Oh JE, Bellone S, Siegel ER, et al
    Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
    Clin Cancer Res. 2024;30:1768-1777.
    >> Share

  54. KHUSHMAN MM, Toboni MD, Xiu J, Manne U, et al
    Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Clin Cancer Res. 2024;30:1906-1915.
    >> Share

  55. MIZUMOTO Y, Kyo S, Kiyono T, Takakura M, et al
    Editor's Note: Activation of NF-kappaB Is a Novel Target of KRAS-induced Endometrial Carcinogenesis.
    Clin Cancer Res. 2024;30:1995.
    >> Share

    April 2024
  56. LORENTZEN GM, Laniewski P, Cui H, Mahnert ND, et al
    Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification.
    Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2934.
    >> Share

  57. SON J, Zhang Y, Lin H, Mirallas O, et al
    Clinical and genomic landscape of RAS mutations in gynecologic cancers.
    Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2819.
    >> Share

  58. SIVARS L, Jylha C, Crona Guterstam Y, Zupancic M, et al
    Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3941.
    >> Share

  59. NIEF CA, Hammer PM, Wang A, Charu V, et al
    Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3158.
    >> Share

  60. YANIZ-GALENDE E, Zeng Q, Grau-Bejar JF, Klein C, et al
    Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3836.
    >> Share

  61. CHAMBERS L, Haight P, Chalif J, Mehra Y, et al
    Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research.
    Clin Cancer Res. 2024 Apr 25. doi: 10.1158/1078-0432.CCR-23-2570.
    >> Share

  62. VENEZIANI AC, Sneha S, Oza AM
    Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
    Clin Cancer Res. 2024;30:1434-1437.
    >> Share

  63. GITTO SB, Whicker M, Davies G, Kumar S, et al
    A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
    Clin Cancer Res. 2024;30:1567-1581.
    >> Share

    March 2024
  64. JAMIESON A, Sobral de Barros J, Cochrane DR, Douglas JM, et al
    Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3689.
    >> Share

  65. KALOGERA E, Nevala WK, Finnes HD, Suman VJ, et al
    A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
    Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3196.
    >> Share

  66. DERMAWAN JK, Chiang S, Singer S, Jadeja B, et al
    Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
    Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-24-0148.
    >> Share

    January 2024
  67. TAN TJ, Sammons S, Im YH, She L, et al
    Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-2513.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016